Hsbc Holdings PLC Boosts Stock Position in Denali Therapeutics Inc. $DNLI

Key Points

• Hsbc Holdings PLC increased its stake in Denali Therapeutics by 73.7% during Q1, owning 58,003 shares valued at approximately $779,000.
• Denali Therapeutics has a current consensus rating of Buy from analysts, with a consensus target price of $33.62.
• In recent insider trading, CEO Ryan J. Watts sold 495,282 shares for over $7.4 million, significantly reducing his stake in the company by 66.18%.

Hsbc Holdings PLC boosted its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 73.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,003 shares of the company's stock after purchasing an additional 24,613 shares during the quarter. Hsbc Holdings PLC's holdings in Denali Therapeutics were worth $779,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. SG Americas Securities LLC increased its holdings in shares of Denali Therapeutics by 339.6% in the 1st quarter. SG Americas Securities LLC now owns 48,365 shares of the company's stock worth $658,000 after buying an additional 37,362 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Denali Therapeutics by 4.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 85,075 shares of the company's stock worth $1,733,000 after acquiring an additional 3,411 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Denali Therapeutics during the first quarter worth approximately $254,000. GAMMA Investing LLC raised its position in Denali Therapeutics by 253.8% during the first quarter. GAMMA Investing LLC now owns 7,953 shares of the company's stock valued at $108,000 after purchasing an additional 5,705 shares during the period. Finally, First Trust Advisors LP lifted its stake in shares of Denali Therapeutics by 260.9% in the 4th quarter. First Trust Advisors LP now owns 65,442 shares of the company's stock valued at $1,334,000 after purchasing an additional 47,308 shares during the last quarter. Institutional investors own 92.92% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on DNLI shares. Robert W. Baird cut their target price on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th. TD Cowen raised shares of Denali Therapeutics to a "strong-buy" rating in a research note on Monday, July 28th. Wedbush reduced their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. HC Wainwright dropped their target price on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Bank of America cut their target price on Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $33.62.

Denali Therapeutics Stock Performance

Denali Therapeutics stock opened at $15.27 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.27 and a current ratio of 10.27. The company has a market capitalization of $2.23 billion, a PE ratio of -5.45 and a beta of 1.36. The company has a 50 day moving average price of $14.44 and a 200-day moving average price of $14.82. Denali Therapeutics Inc. has a fifty-two week low of $10.57 and a fifty-two week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.02. During the same period in the previous year, the company earned ($0.59) EPS. As a group, equities analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Insider Activity

In other Denali Therapeutics news, CEO Ryan J. Watts sold 495,282 shares of the firm's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total transaction of $7,429,230.00. Following the transaction, the chief executive officer owned 253,071 shares of the company's stock, valued at approximately $3,796,065. This trade represents a 66.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Carole Ho sold 2,937 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the sale, the insider owned 217,391 shares of the company's stock, valued at approximately $2,952,169.78. This represents a 1.33% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 501,962 shares of company stock worth $7,520,799. Company insiders own 12.50% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.